Overview

Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients

Status:
NOT_YET_RECRUITING
Trial end date:
2030-01-31
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of glumetinib combined with osimertinib as the first-line treatment for locally advanced or metastatic NSCLC.
Phase:
PHASE2
Details
Lead Sponsor:
Shanghai JMT-Bio Inc.
Treatments:
glumetinib
osimertinib